PDSB
PDS Biotechnology Corp
NASDAQ · Healthcare · Biotechnology · US
$0.81
−4.36%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.84
From 52W high−43.67%
Volume18.56M
Market cap$58.38M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.84
From 52W high
−43.67%
Volume
18.56M
Market cap
$58.38M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
66.9
MomentumView details →
1D Return
−4.36%
YTD Return
+0.48%
SummaryUpdated Jun 1, 2026
PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Florham Park, New Jersey. The company focuses on developing multifunctional cancer immunotherapies using its proprietary Versamune platform technology. Since going public in 2015, PDS has advanced multiple product candidates through clinical trials, with its lead program targeting HPV-positive cancers currently in Phase 3 development. The company operates as a pure-play biotechnology firm with no current revenue, relying on clinical trial advancement and potential partnerships to drive value creation.
Similar companies
Latest newsMore news →
PDS Biotechnology Corp amended its $6,000,000 promissory note with YA II PN, Ltd., modifying payment and cure-period terms, including a mandatory deemed redemption of proceeds from non-ATM equity financings.16d agoPDS Biotechnology Corp terminated Stephan Toutain as Chief Operating Officer, effective August 21, 2026, with severance of twelve months' base salary and COBRA contributions.27d agoLars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corp, effective September 12, 2026, and Janetta Trochimiuk was appointed interim Principal Accounting Officer effective the same date.33d ago